Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study


Demirci N. S., AKSOY S., ÖZDEMİR N., Erdem G. U., Ozcelik M., Tanrikulu E., ...Daha Fazla

CURRENT MEDICAL RESEARCH AND OPINION, cilt.33, sa.3, ss.401-407, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 3
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1080/03007995.2016.1257984
  • Dergi Adı: CURRENT MEDICAL RESEARCH AND OPINION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.401-407
  • Anahtar Kelimeler: Cisplatin, docetaxel, fluorouracil, head and neck, cancer, metastasis, modified DCF, recurrence, COOPERATIVE-ONCOLOGY-GROUP, MULTICENTER PHASE-II, METASTATIC HEAD, PLUS CETUXIMAB, RANDOMIZED-TRIAL, OPEN-LABEL, RECURRENT, CHEMOTHERAPY, 5-FLUOROURACIL, METHOTREXATE
  • Marmara Üniversitesi Adresli: Evet

Özet

Aim: Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) therapy has been shown to be a well tolerated and highly effective regimen for metastatic gastric carcinoma. Herein we investigated the effectiveness of the mDCF combination as the first-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (HNSCC).